The cancer therapy developer has now collected more than $240m altogether, having completed a series C round that included Roche Venture Fund.

Alexandria Venture Investments returned for a series B round that increased the precision oncology drug developer's overall funding to over $150m.

Chief executive Antonin de Fougerolles talks about Evox’s journey to commercialising a new modality that could prove truly transformational.

The University of Bristol spinout is working on adapting cell therapies to solid tumours.

Fungal infection treatment developer Amplyx Pharmaceuticals had disclosed $142m in funding from investors including Pfizer and Lundbeckfonden Ventures.

Applied Ventures helped assay provider Ultivue close a $50m round while clean energy producer Sunseap has followed a $72m series D4 round with more corporate funding.

The artificial intelligence drug developer has closed a $225m round led by SoftBank Vision Fund 2, which has offered a further $300m in funding.

Alphabet early-stage investment unit GV has added two biotechnology professionals, Dan Lynch and Mojca Skoberne, to its team.

Allied Minds portfolio company OcuTerra Therapeutics has secured $14.6m in funding.

CSIRO-founded Main Sequence Ventures has pocketed $194m for its second fund, which has added decarbonisation to the firm’s list of targeted technologies.